Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mangalam Drugs & Organics Ltd. ( (IN:MANGALAM) ) has issued an update.
Mangalam Drugs & Organics Ltd. announced the approval of its un-audited financial results for the quarter ending June 30, 2025. The company reported a net loss of Rs. 1,372.80 lakhs for the quarter, compared to a profit in the previous quarter, indicating a challenging financial period. The results were reviewed by statutory auditors who did not express any modified opinions. This financial performance may impact the company’s market positioning and stakeholder confidence.
More about Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of active pharmaceutical ingredients (APIs) and other drug-related products. The company is headquartered in Mumbai, India, and has a manufacturing facility in Vapi, Gujarat.
Average Trading Volume: 5,519
Technical Sentiment Signal: Sell
Current Market Cap: 1.39B INR
Find detailed analytics on MANGALAM stock on TipRanks’ Stock Analysis page.